4.6 Article

Decreased phosphatidylcholine plasmalogens - A putative novel lipid signature in patients with stable coronary artery disease and acute myocardial infarction

期刊

ATHEROSCLEROSIS
卷 246, 期 -, 页码 130-140

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2016.01.003

关键词

Glycerophospholipids; Sphingolipids; Coronary artery disease; Acute myocardial infarction

资金

  1. Zurich Center of Integrated Human Physiology, University of Zurich (ZIHP)
  2. Foundation for Pathobiochemistry and Molecular Diagnostics of the German Society for Clinical Chemistry and Laboratory Medicine
  3. Swiss National Science Foundation [SPUM 33CM30-124112]
  4. Swiss Heart Foundation
  5. Fondation Leducq
  6. Foundation for Cardiovascular Research, Zurich
  7. Roche
  8. Eli Lilly (USA)
  9. AstraZeneca (Switzerland)
  10. Medtronic (Switzerland)
  11. MSD (Switzerland)
  12. Sanofi (Switzerland)
  13. St. Jude Medical (Switzerland)

向作者/读者索取更多资源

Objective: Glycerophospholipids and sphingolipids are structurally heterogeneous due to differences in the O-and N-linked fatty acids and head groups. Sphingolipids also show a heterogeneity in their sphingoid base composition which up to now has been little appreciated. The aim of this study was to investigate the association of certain glycerophospholipid and sphingolipid species with stable coronary artery disease (CAD) and acute myocardial infarction (AMI). Methods: The lipid profile in plasma from patients with stable CAD (n = 18) or AMI (n = 17) was compared to healthy subjects (n = 14). Sixty five glycerophospholipid and sphingolipid species were quantified by LC-MS. The relative distribution of these lipids into lipoprotein fractions was analyzed. Results: In the CAD cohort, 45 glycerophospholipid and sphingolipid species were significantly lower compared to healthy controls. In the AMI group, 42 glycerophospholipid and sphingolipid species were reduced. Four PC plasmalogens (PC33: 1, PC33: 2, PC33: 3 and PC35: 3) showed the most significant difference. Out of eleven analyzed sphingoid bases, four were lower in the CAD and six in the AMI group. Sphingosine-1-phosphate (S1P) levels were reduced in the AMI group whereas an atypical C16: 1 S1P was lower in both groups. Phosphatidylcholine and sphingomyelin species were exclusively present in lipoprotein particles, whereas lysophosphatidylcholines were mainly found in the lipoprotein-free fraction. The observed differences were not explained by the use of statins as confirmed in a second, independent cohort. Conclusions: Reduced levels of four PC plasmalogens (PC33: 1, PC33: 2, PC33: 3 and PC35: 3) were identified as a putatively novel lipid signature for CAD and AMI. (C) 2016 Elsevier Ireland Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据